Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry.

4-Methylthioamphetamine (4-MTA) is a scheduled designer drug that has appeared on the illicit drug market and led to several non-fatal or even fatal poisonings. Only few data are available on its metabolism. The first aim of this study was to identify the 4-MTA metabolites in human urine and then to study whether the authors' STA procedure is suitable for screening for and identification of 4-MTA and/or its metabolites in urine. After enzymatic cleavage of conjugates, solid-phase extraction (SPE) and acetylation the following metabolites could be identified by full-scan gas chromatography-mass spectrometry (GC-MS): deamino-oxo 4-MTA, deamino-hydroxy 4-MTA, ring hydroxy and beta-hydroxy 4-MTA. 4-MTA sulfoxide could be identified as possible artifact. In urine samples after enzymatic hydrolysis, acidic extraction, and methylation, 4-methylthiobenzoic acid could be identified. The authors' systematical toxicological analysis (STA) procedure using full-scan GC-MS after acid hydrolysis, liquid-liquid extraction (LLE) and acetylation allowed detection of 4-MTA as target analyte plus all the above-mentioned metabolites with the exception of 4-methylthiobenzoic acid. The extraction efficiency of 4-MTA was approximately 70% and the limit of detection (LOD) was 30 ng/ml (S/N 3).

[1]  F. Peters,et al.  Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. , 2003, Journal of mass spectrometry : JMS.

[2]  D. Marona-Lewicka,et al.  p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. , 1992, European journal of pharmacology.

[3]  D. Cannon,et al.  In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine. , 2002, European journal of pharmacology.

[4]  K. Kovar,et al.  Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. , 1996, Journal of chromatography. B, Biomedical applications.

[5]  E. Kováts,et al.  Gas‐chromatographische Charakterisierung organischer Verbindungen. Teil 1: Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde und Ketone , 1958 .

[6]  F. McLafferty.  Interpretation of Mass Spectra , 1966 .

[7]  R. Smith,et al.  Understanding Mass Spectra: A Basic Approach , 1998 .

[8]  J. Ramsey,et al.  4-MTA: a new synthetic drug on the dance scene. , 2002, Drug and alcohol dependence.

[9]  S. Elliott.  Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). , 2000, Journal of analytical toxicology.

[10]  H. Maurer,et al.  Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. , 2003, Journal of analytical toxicology.

[11]  H. Maurer,et al.  New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. , 2003, Journal of mass spectrometry : JMS.

[12]  H. Maurer,et al.  Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  H. Maurer,et al.  Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. , 2000, Journal of analytical toxicology.

[14]  M. Gobbi,et al.  p‐Methylthioamphetamine and 1‐(m‐chlorophenyl)piperazine, two non‐neurotoxic 5‐HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5‐HT nerve endings in vitro , 2002, Journal of neurochemistry.

[15]  F. Oesch,et al.  Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  H. Maurer,et al.  New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. , 2004, Journal of mass spectrometry : JMS.

[17]  Hans H Maurer,et al.  Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control , 2004, Clinical chemistry and laboratory medicine.

[18]  H. Maurer,et al.  New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  W. Lambert,et al.  Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. , 2001, Journal of analytical toxicology.

[20]  H. Maurer.  On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. , 1996, Therapeutic drug monitoring.

[21]  F. Carvalho,et al.  Identification of 4-methylthioamphetamine and some of its metabolites in mouse urine by GC-MS after acute administration. , 2002, Journal of analytical toxicology.

[22]  M. Piette,et al.  One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings , 2001, International Journal of Legal Medicine.